- Intec Pharma (NASDAQ:NTEC) Q2 results: Revenues: $0; R&D Expense: $1.3M (+225.0%); SG&A: $0.8M (+60.0%); Operating Loss: ($2.1M) (-110.0%); Net Loss: ($2M) (-122.2%); Loss Per Share: ($0.18) (-12.5%); Quick Assets: $19.5M (-31.8%); CF Ops: ($9.4M) (-176.5%).
- Shares up 7% premarket on increased volume.
- No guidance given.